Tesla And xAI To Continue Buying Nvidia Microchips, Says Elon Musk
Elon Musk said in an interview on CNBC that Tesla (TSLA) and his artificial intelligence (A.I.) start-up company xAI will continue buying lots of microchips from Nvidia (NVDA). xAI, which now owns social media company X (formerly known as Twitter), has already installed 200,000 Nvidia graphics processing units (GPUs) at its facility in Memphis, Tennessee. Musk says that the privately held A.I. start-up is also planning a one million GPU facility outside the City of Memphis.Musk did not specify exactly how many microchips his companies plan to order or say when xAI might buy more chips from Nvidia, as well as Advanced Micro Devices (AMD). However, over the past year, Musk has directed Nvidia to send a large order of GPUs to xAI first, ahead of electric vehicle maker Tesla.Musk said Tesla’s Dojo supercomputer also has a need for microchips and processors, which are used for training Tesla’s autopilot feature and the company’s Optimus robotics systems.Musk boasted in the interview that xAI’s facility in Memphis is the “most powerful training cluster in the world right now” with “over 200,000 GPUs training coherently.” The demand by Musk’s various companies for advanced microchips and processors is good news for both Nvidia and AMD, and their future sales. Nvidia’s stock has fallen 3% this year to trade at $134.38 U.S. per share.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


